FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:545-546 August 16, 2001 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: In their article on the polysaccharide conjugate typhoid vaccine Vi-rEPA, Lin et al. (April 26 issue)¹ report an efficacy of 91.5 percent in the prevention of typhoid fever due to the development of IgG Vi antibodies, and they presume that the vaccination can help in the prevention of typhoid fever and in limiting the spread of multidrug-resistant enteric fever.

There were five cases of typhoid fever in the vaccine group, even though the serum levels of IgG Vi antibodies increased by a factor of at least 10 in 100 percent of the children. The levels of IgG . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.